Local Control by Mediastinal Lymph-Node Dissection in Stage I Non-Small-Cell Lung Cancer
Interdisciplinary CardioVascular and Thoracic Surgery · 01.07.2026 · 41 (7)
DOI: 10.1093/icvts/ivag189 ↗Kurz gefasst
Fachartikel in der Zeitschrift Interdisciplinary CardioVascular and Thoracic Surgery, online erschienen am 21.07.2026. Verfasst von Shunsuke Morita und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, Hiroshima University, Hiroshima, 734-8551, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Lymph Node Excision, Pneumonectomy. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Mediastinal lymph-node dissection (MLND) is recommended for resectable non-small-cell lung cancer (NSCLC); however, its prognostic impact remains controversial. We evaluated whether MLND improves prognosis in patients with radiologically solid-dominant clinical stage I NSCLC.
Methods
We retrospectively reviewed 2212 patients who underwent lobectomy for solid-dominant clinical stage I NSCLC between 2010 and 2022. Prognosis and local control were compared between the MLND and non-MLND groups.
Results
The MLND and non-MLND groups included 1912 and 300 patients, respectively. After propensity score matching, 5-year overall survival did not show a statistically significant difference between the groups (85.3% vs 79.3%, P = .089). MLND identified occult pN2 metastasis in 7.3% (138/1912) of patients. Notably, 3.6% (68/1912) of the entire MLND cohort had pN2 disease yet remained recurrence-free. Furthermore, the MLND group demonstrated significantly lower mediastinal lymph-node recurrence than the non-MLND group (P = .017). Among patients with pN2 disease in the MLND group, those with recurrence (n = 70) had a higher incidence of intrapulmonary metastases (P = .042), a higher number of mediastinal lymph-node metastases (P = .002), and a lower rate of skip-N2 involvement (P = .031).
Conclusions
Mediastinal lymph-node dissection provides superior local control by reducing mediastinal recurrences and enables accurate pathological staging. While this advantage guides appropriate adjuvant therapy selection, the direct impact of MLND on overall survival remains uncertain. Its true survival benefit should be evaluated in future prospective randomized trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgical Oncology, Hiroshima University, Hiroshima, 734-8551, Japan.
- Department of Surgery, Tokyo Medical University, Tokyo, 160-0023, Japan.
- Department of Thoracic Surgery, Kanagawa Cancer Center, Yokohama, 241-8515, Japan.
ORCID-Profile: Shunsuke Morita, Takahiro Mimae, Norifumi Tsubokawa, Hiroyuki Ito
Zitieren
APA
Morita, S., Mimae, T., Kudo, Y., Nagashima, T., Tsubokawa, N., Miyata, Y., Ito, H., Ikeda, N., & Okada, M. (2026). Local Control by Mediastinal Lymph-Node Dissection in Stage I Non-Small-Cell Lung Cancer. Interdisciplinary CardioVascular and Thoracic Surgery, 41(7). https://doi.org/10.1093/icvts/ivag189
Vancouver
Morita S, Mimae T, Kudo Y, Nagashima T, Tsubokawa N, Miyata Y, et al. Local Control by Mediastinal Lymph-Node Dissection in Stage I Non-Small-Cell Lung Cancer. Interdisciplinary CardioVascular and Thoracic Surgery. 2026;41(7). doi:10.1093/icvts/ivag189
BibTeX
@article{Morita2026,
author = {Morita, Shunsuke and Mimae, Takahiro and Kudo, Yujin and Nagashima, Takuya and Tsubokawa, Norifumi and Miyata, Yoshihiro and Ito, Hiroyuki and Ikeda, Norihiko and Okada, Morihito},
title = {Local Control by Mediastinal Lymph-Node Dissection in Stage I Non-Small-Cell Lung Cancer},
journal = {Interdisciplinary CardioVascular and Thoracic Surgery},
year = {2026},
volume = {41},
number = {7},
doi = {10.1093/icvts/ivag189}
}
EUVIMED